Coronary heart disease (CHD) is a common form of heart disease. The main blood vessels supplying the heart (coronary arteries) have difficulty delivering enough blood, oxygen, and nutrients to the heart muscle. Cholesterol deposits (plaque) and inflammation in the heart's arteries are often the cause of coronary artery disease.
Signs and symptoms of CHD occur when the heart does not receive enough oxygen-rich blood. CHD usually develops over decades. However, as the patient's arteries narrow, mild symptoms may develop, the most common being chest pain or shortness of breath. This indicates that the heart is pumping harder to deliver oxygen-rich blood to the body. Such minor symptoms may go unnoticed until a serious blockage causes problems or a heart attack occurs.
Angiogenesis, the growth of new collateral vessels, is a natural biological response to recurrent myocardial ischemia. These newly formed vessels provide an alternative pathway for blood flow and oxygen delivery to the part of the patient's heart downstream of coronary artery obstruction. However, in many patients, including those with recurrent angina, the formation of coronary collateral vessels is not sufficient to meet the needs of the heart during periods of stress. Currently available anti-anginal drugs, which provide symptomatic relief, are usually designed to alter myocardial oxygen demand or dilate blood vessels to temporarily relieve angina.
Medications can help control a patient's CHD symptoms and prevent or treat heart disease. Among them, alferminogene tadenovec is considered a realistic treatment option for myocardial ischemia in specific patient populations. Alferminogene tadenovec is a replication-deficient human adenovirus serotype 5, which encodes human FGF4, an angiogenic protein that enhances neointima formation.
Alferminogene tadenovec has the potential to promote improved amelioration of the disease by harnessing the body's natural healing process in response to myocardial ischemia (inadequate blood flow and myocardial oxygen supply). They are designed to promote the heart's natural response to collateral growth and increase blood flow in the microcirculation. In phase, I and II clinical trials, the administration of alferminogene tadenovec was well tolerated and significantly improved treadmill exercise capacity. A phase III clinical trial is currently evaluating alferminogene tadenovec as a therapy for myocardial ischemia in women who are not candidates for revascularization.
Alferminogene tadenovec represents a new therapeutic class of biologics, and Creative BioMart , as always, is focused on its great potential to promote angiogenesis and increase blood flow in microcirculation. We offer our customers in the CHD research field a high-quality alferminogene tadenovec product for the potential treatment of myocardial ischemia. Please feel free to contact us for the latest news. We are pleased to work with you to find new avenues for more patients in the field of CHD.
For more information on how our products could help advance your project, please contact us.
ENTER YOUR EMAIL HERE TO SUBSCRIBE.
Copyright © Creative BioMart. All Rights Reserved.